Alvotech (ALVO) vs Viridian Therapeutics, Inc. (VRDN)

A side-by-side comparison of Alvotech and Viridian Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ALVO vs VRDN

growth of $100 · dividends reinvested · last 4y
ALVO -45.4% (-14.0%/yr)VRDN +77.6% (+15.4%/yr)VRDN compounded faster over this window
100200300Start $1002023202420252026$55$178
ALVO VRDN

ALVO vs VRDN: by the numbers

  • •ALVO is the larger company ($2.08B vs $2.06B market cap).
  • •Both run net losses; ALVO's is the smaller (-36.51% vs -544.06% net margin).
  • •VRDN grew revenue faster over the past five years (93.92% vs 69.03% CAGR).

Metrics side by side

Valuation

MetricALVOVRDN
P/S ratio4.2229.02
P/B ratioN/A3.66
EV / EBITDA41.97N/A

Profitability

MetricALVOVRDN
Gross margin60.45%99.55%
Operating margin9.62%-512.91%
Net margin-36.51%-544.06%
ROEN/A-58.45%
ROIC3.61%-39.18%

Growth (annualized)

MetricALVOVRDN
Revenue CAGR (5Y)69.03%93.92%
Total return CAGR (5Y)N/A1.64%

Frequently asked

Which has grown faster, ALVO or VRDN?
Over the past five years, VRDN grew revenue faster — ALVO at a 69.03% CAGR versus VRDN at 93.92%.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.